Breast Cancer

Dr Pegram discusses approaches to treatment sequencing in HER2-positive metastatic breast cancer, the influence of the DESTINY-Breast03 trial (NCT03529110) on the breast cancer treatment paradigm, and ongoing research in the field.

Closing out her discussion on HER2+ metastatic breast cancer, Cynthia Lynch, MD, shares her excitement for treatment strategies in the setting of brain metastases.

Entrectinib produced deep and durable responses in patients with breast cancer harboring NTRK fusions.

Shared insight on specific treatment options in breast cancer made available when patients are found to have actionable targets via molecular testing.

Expert perspectives on platforms for molecular testing in breast cancer, as well as the actionable targets that treating physicians should be looking for.

Heidi Ko, DO, discusses unmet needs in patients with PD-L1–negative triple negative breast cancer.

The addition of abemaciclib to endocrine therapy improved invasive disease-free survival and distant relapse-free survival vs endocrine therapy alone in patients with high-risk, hormone receptor–positive, HER2-negative, early-stage breast cancer, irrespective of menopausal status.

The addition of nivolumab to trastuzumab deruxtecan did not result in a marked clinical benefit in patients with locally advanced unresectable or metastatic HER2-positive breast cancer.

Virginia G. Kaklamani, MD, discussed the emerging role of PARP inhibitors, practice-changing updates in HER2-positive breast cancer, the utilization of CDK4/6 inhibitors in hormone receptor–positive, HER2-negative breast cancer, and the various therapeutic classes and their effects on care in triple-negative breast cancer.

HER2 expression appeared to be a significant predictor for response to fam-trastuzumab deruxtecan-nxki, according to findings from a biomarker analysis of patients with metastatic breast cancer in the phase 2 DAISY trial.

The addition of adjuvant abemaciclib to endocrine therapy resulted in a clinically meaningful reduction in the risk of developing invasive disease, particularly incurable distant metastatic disease, in patients with high-risk, hormone receptor–positive, HER2-negative, early breast cancer who comprised cohort 1 of the phase 3 monarchE trial.

Nearly all patients with HER2-positive breast cancer with brain metastases who received fam-trastuzumab deruxtecan-nxki elicited benefit, according to data from a primary outcome analysis of the phase 2 TUXEDO-1 trial.

The combination of alpelisib plus endocrine therapy elicited a clinical benefit across all subgroups of patients with hormone receptor–positive, HER2-negative advanced breast cancer with PIK3CA mutations.

Heather McArthur, MD, MPH, discusses the FDA approval of fam-trastuzumab deruxtecan-nxki for second-line treatment in HER2-positive metastatic breast cancer.

Overall health status and quality of life were maintained among patients with HER2-positive metastatic breast cancer who were treated with fam-trastuzumab deruxtecan-nxki compared with those who received ado-trastuzumab emtansine.

Neoadjuvant therapy generated similar benefits to adjuvant therapy in patients with early-stage, HER2-positive breast cancer treated in China, suggesting that neoadjuvant therapy should be used in this patient population.

Sacituzumab govitecan-hziy maintained clinical benefit in patients with metastatic triple-negative breast cancer regardless of HER2 expression according to a post hoc analysis of the phase 3 ASCENT trial.

The addition of ribociclib to fulvestrant continued to significantly prolong overall survival, delayed time to second disease progression, and improved chemotherapy-free survival vs placebo plus fulvestrant in the first-line treatment of patients with advanced hormone receptor–positive, HER2-negative breast cancer.

In the context of recently approved novel regimens, expert Cynthia Lynch, MD, revisits the optimal sequencing of therapy for patients with HER2+ metastatic breast cancer.

Marcela Mazo Canola, MD, discusses pivotal trials in early-stage and metastatic HER2-positive breast cancer, plus ongoing trials to watch.

Data from the HER2CLIMB, NALA, and SOPHIA trials that led to the FDA approval of respective agents in the setting of HER2+ metastatic breast cancer.

The FDA has approved fam-trastuzumab deruxtecan-nxki for adult patients with unresectable or metastatic HER2-positive breast cancer who have previously received an anti–HER2-based regimen either in the metastatic setting, or in the neoadjuvant or adjuvant setting, and have developed disease recurrence during or within 6 months of therapy completion.

Elias Obeid, MD, MPH, discusses the phase 3 KATHERINE trial in HER2-positive breast cancer.

Kevin Kalinsky, MD, MS, discusses updates from the phase 3 TAILORx trial in patients with hormone receptor–positive or HER2-negative breast cancer with node-negative disease.

Heather McArthur, MD, MPH, discusses key treatment developments in early-stage and metastatic HER2-positive breast cancer and triple-negative breast cancer, plus ongoing research at UT Southwestern Harold C. Simmons Comprehensive Cancer Center.